Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


06.11.2017

1 Anticancer Res
2 BJU Int
1 BMC Cancer
1 BMC Urol
4 Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Imaging
4 Eur Urol
2 Invest Radiol
1 J Nucl Med
1 Mod Pathol
5 N Engl J Med
2 Nat Rev Urol
1 Oncol Rep
2 Oncology (Williston Park)
1 Proc Natl Acad Sci U S A
5 Prostate
1 Radiology
5 Urol Int
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. WIKSTROM J, Isacsson U, Johansson B, Lennernas BO, et al
    Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning - A Phantom Study.
    Anticancer Res. 2017;37:4993-4996.
    PubMed     Text format     Abstract available


    BJU Int

  2. YAXLEY AJ, Yaxley JW, Thangasamy IA, Ballard E, et al
    Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    BJU Int. 2017;120 Suppl 3:43-50.
    PubMed     Text format     Abstract available

  3. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. KIRKMAN M, Young K, Evans S, Millar J, et al
    Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia.
    BMC Cancer. 2017;17:704.
    PubMed     Text format     Abstract available


    BMC Urol

  5. FITCH M, Pang K, Ouellet V, Loiselle C, et al
    Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources.
    BMC Urol. 2017;17:98.
    PubMed     Text format     Abstract available


    Cancer

  6. MAHAL AR, Mahal BA, Nguyen PL, Yu JB, et al
    Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.
    Cancer. 2017 Oct 30. doi: 10.1002/cncr.31106.
    PubMed     Text format     Abstract available

  7. GONZALEZ BD, Small BJ, Cases MG, Williams NL, et al
    Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31024.
    PubMed     Text format     Abstract available

  8. ALBISINNI S, Joniau S, Quackels T, De Coster G, et al
    Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium.
    Cancer. 2017;123:4139-4146.
    PubMed     Text format     Abstract available

  9. FREEDLAND SJ, Vidal AC, Howard LE, Terris MK, et al
    Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Cancer. 2017;123:4199-4206.
    PubMed     Text format     Abstract available


    Cancer Lett

  10. KOLLURU V, Pal D, Papu John AMS, Ankem MK, et al
    Induction of Plac8 promotes pro-survival function of autophagy in cadmium-induced prostate carcinogenesis.
    Cancer Lett. 2017;408:121-129.
    PubMed     Text format     Abstract available


    Cancer Res

  11. DAMASCHKE NA, Yang B, Bhusari S, Avilla M, et al
    Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
    Cancer Res. 2017;77:5236-5247.
    PubMed     Text format     Abstract available


    Clin Imaging

  12. HAUTH E, Jaeger H, Hohmuth H, Beer M, et al
    Follow-up MR imaging of PI-RADS 3 and PI-RADS 4 prostate lesions.
    Clin Imaging. 2017;43:64-68.
    PubMed     Text format     Abstract available


    Eur Urol

  13. HEINZELBECKER J, Stockle M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30899.
    PubMed     Text format    

  14. LAVAUD P, Gravis G, Foulon S, Joly F, et al
    Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Eur Urol. 2017 Oct 23. pii: S0302-2838(17)30791.
    PubMed     Text format     Abstract available

  15. ASSEL M, Dahlin A, Ulmert D, Bergh A, et al
    Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860.
    PubMed     Text format     Abstract available

  16. SAITO K, Fujii Y
    Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
    Eur Urol. 2017 Oct 20. pii: S0302-2838(17)30858.
    PubMed     Text format    


    Invest Radiol

  17. LAGEMAAT MW, Philips BW, Vos EK, van Uden MJ, et al
    Feasibility of Multiparametric Magnetic Resonance Imaging of the Prostate at 7 T.
    Invest Radiol. 2017;52:295-301.
    PubMed     Text format     Abstract available

  18. WEISS J, Martirosian P, Notohamiprodjo M, Kaufmann S, et al
    Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy.
    Invest Radiol. 2017 Oct 26. doi: 10.1097/RLI.0000000000000427.
    PubMed     Text format     Abstract available


    J Nucl Med

  19. MINAMIMOTO R, Sonni I, Hancock S, Vasanawala S, et al
    Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging.
    J Nucl Med. 2017 Oct 30. pii: jnumed.117.197624. doi: 10.2967/jnumed.117.197624.
    PubMed     Text format     Abstract available


    Mod Pathol

  20. LI H, Wang Z, Xiao W, Yan L, et al
    Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.
    Mod Pathol. 2017 Oct 27. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    N Engl J Med

  21. ISMAILI N, Guessous F
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1695-6.
    PubMed     Text format    

  22. JAMES ND, Spears MR, Sydes MR
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1696-7.
    PubMed     Text format    

  23. DE BONO J, Eisenberger M, Sartor O
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1694-5.
    PubMed     Text format    

  24. FIZAZI K, Chi KN
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1697-8.
    PubMed     Text format    

  25. TANNOCK IF
    Abiraterone in Metastatic Prostate Cancer.
    N Engl J Med. 2017;377:1695.
    PubMed     Text format    


    Nat Rev Urol

  26. THOMA C
    Prostate cancer: Modelling Intraductal Carcinoma.
    Nat Rev Urol. 2017;14:641.
    PubMed     Text format    

  27. SFANOS KS, Yegnasubramanian S, Nelson WG, De Marzo AM, et al
    The inflammatory microenvironment and microbiome in prostate cancer development.
    Nat Rev Urol. 2017 Oct 31. doi: 10.1038/nrurol.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  28. LING Z, Liu D, Zhang G, Liang Q, et al
    miR-361-5p modulates metabolism and autophagy via the Sp1-mediated regulation of PKM2 in prostate cancer.
    Oncol Rep. 2017;38:1621-1628.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  29. TENDULKAR R
    Point: Early Salvage vs Adjuvant Radiotherapy for High-Risk Prostate Cancer.
    Oncology (Williston Park). 2017;31:750-2.
    PubMed     Text format    

  30. WU WJ, Potters L
    Counterpoint: Early Salvage vs Adjuvant Radiotherapy for High-Risk Prostate Cancer.
    Oncology (Williston Park). 2017;31:750.
    PubMed     Text format    


    Proc Natl Acad Sci U S A

  31. KUNDU M, Roy A, Pahan K
    Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-gamma.
    Proc Natl Acad Sci U S A. 2017;114:11482-11487.
    PubMed     Text format     Abstract available


    Prostate

  32. BONKHOFF H
    Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23446.
    PubMed     Text format     Abstract available

  33. KATO M, Kimura K, Hirakawa A, Kobayashi Y, et al
    Prognostic parameter for high risk prostate cancer patients at initial presentation.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23438.
    PubMed     Text format     Abstract available

  34. TJON-KON-FAT LA, Lundholm M, Schroder M, Wurdinger T, et al
    Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23443.
    PubMed     Text format     Abstract available

  35. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
    Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
    Prostate. 2017;77:1592-1600.
    PubMed     Text format     Abstract available

  36. ZHOU CK, Stanczyk FZ, Hafi M, Veneroso CC, et al
    Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
    Prostate. 2017;77:1573-1582.
    PubMed     Text format     Abstract available


    Radiology

  37. KUHL CK, Bruhn R, Kramer N, Nebelung S, et al
    Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.
    Radiology. 2017 Jul 20:170129. doi: 10.1148/radiol.2017170129.
    PubMed     Text format     Abstract available


    Urol Int

  38. TANG Y, Liu Z, Tang L, Zhang R, et al
    Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis.
    Urol Int. 2017 Oct 30. doi: 10.1159/000484144.
    PubMed     Text format     Abstract available

  39. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    PubMed     Text format     Abstract available

  40. LAI P, Luo M, Hu G, Liu H, et al
    Primary Urothelial Carcinoma of the Prostate with Glandular Differentiation: A Case Report.
    Urol Int. 2017;98:370-372.
    PubMed     Text format     Abstract available

  41. PEETERS C, Ponette D, van Poppel H
    Salvage Pelvic Lymph Node Dissection after Radical Prostatectomy for Biochemical and Lymph Node Recurrence.
    Urol Int. 2017;98:367-369.
    PubMed     Text format     Abstract available

  42. HIRASAWA Y, Yoshioka K, Nasu Y, Yamamoto M, et al
    Impact of Surgeon and Hospital Volume on the Safety of Robot-Assisted Radical Prostatectomy: A Multi-Institutional Study Based on a National Database.
    Urol Int. 2017;98:334-342.
    PubMed     Text format     Abstract available


    Urology

  43. ZHONG W, Smith B, Haghighi K, Mancuso P, et al
    Systematic Review of Decision Aids for the Management of Men with Localized Prostate Cancer.
    Urology. 2017 Oct 31. pii: S0090-4295(17)31154.
    PubMed     Text format     Abstract available

  44. SHARMA V, Yousefi K, Haddad Z, Buerki C, et al
    Gene Expression Correlates of Site-Specific Metastasis among Men with Lymph Node Positive Prostate Cancer Treated with Radical Prostatectomy: a Case Series.
    Urology. 2017 Oct 24. pii: S0090-4295(17)31099.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: